Pioneer of Tumor Immunotherapy Dr. Francesco Marincola Appointed as Chairman of Batu Biologics Clinical Advisory Board

Former President of the Society for Immunotherapy of Cancer to Assist Company in Advancement of its Anti-Angiogenesis Immunotherapy Product ValloVax

SAN DIEGO--(EON: Enhanced Online News)--Batu Biologics, committed to advancement of its clinical stage cancer immunotherapeutic, ValloVax™, announced today the appointment of Dr. Francesco Marincola as the Chairman of the Company’s Clinical Advisory Board.

“It is my honor to welcome Dr. Marincola to Chair our Clinical Advisory Board. Having previously worked and published with Dr. Marincola, I am very excited about collaborating in advancing our cancer immunotherapeutic that selectively kills tumor blood vessels”

Dr. Marincola has pioneered research in tumor immunology by developing strategies for studying tumor-host interactions in the context of human genetic polymorphism and cancer heterogeneity. During his tenure as a Senior Staff Scientist with the NCI Surgery Branch, Dr. Marincola investigated the identification of the algorithm responsible for tumor rejection by immune cells particularly in the context of metastatic melanoma. Specifically, the focus of his research is the optimization of strategies to study clinical material during the conduct of clinical trials. Dr. Marincola is author of over 500 peer reviewed papers and is considered one of the world’s top experts in tumor immunotherapy.

“It is my honor to welcome Dr. Marincola to Chair our Clinical Advisory Board. Having previously worked and published with Dr. Marincola, I am very excited about collaborating in advancing our cancer immunotherapeutic that selectively kills tumor blood vessels,” said Samuel Wagner, President and CEO of Batu Biologics.

Batu Biologics has obtained FDA clearance to initiate clinical trials of its ValloVax product which has been published to induce immune responses to what is believed to be the “Achilles Heel” of cancer: its blood supply.

“Despite the great progress that has occurred in the field of immuno-oncology, many patients still do not respond to approaches such as checkpoint inhibitors,” said Dr. Marincola. “I am enthusiastic about leading the scientific direction of the Company as it seeks to develop a totally new approach to cancer immunotherapy.”

Recent Stories

• 
  Batu Biologics Chief Executive Officer Samuel Wagner to Moderate Congressional Immunotherapy Symposium
  March 15, 2018
  SAN DIEGO--(EON: Enhanced Online News)--Batu Biologics, a clinical stage immunotherapy company, announced today its Chief Executive Officer, Samuel Wagner, was chosen to moderate an internationally... more »
• 
  Batu Biologics Successfully Completes $1.3 Million #Starvethetumor Equity Crowdfunding Campaign
  December 25, 2017
  SAN DIEGO--(EON: Enhanced Online News)--Batu Biologics, an immuno-oncology Company dedicated to the development of its clinical stage tumor-angiogenesis targeting immunotherapy, ValloVax™, announce... more »
• Batu Biologics Receives FDA Clearance for First Multi-Pronged Immunotherapy Targeting the Blood Vessels that Feed Cancer
  November 07, 2017
  SAN DIEGO--(EON: Enhanced Online News)--Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, has received an Invest... more »

More Stories